Benitec Biopharma (BNTC) Projected to Post Earnings on Friday

Benitec Biopharma (NASDAQ:BNTC) will likely be announcing its Q2 2026 results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, February 13, 2026 at 4:00 PM ET.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.13. On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Benitec Biopharma Trading Down 6.1%

BNTC stock opened at $11.65 on Friday. The stock has a market capitalization of $399.13 million, a price-to-earnings ratio of -9.63 and a beta of 0.26. The firm’s 50-day moving average price is $12.43 and its two-hundred day moving average price is $13.15. Benitec Biopharma has a 12-month low of $9.70 and a 12-month high of $17.15.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on BNTC shares. Wall Street Zen raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Citizens Jmp raised their price target on shares of Benitec Biopharma from $20.00 to $22.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Zacks Research raised shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. JMP Securities set a $22.00 price objective on Benitec Biopharma in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $26.25.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 77,387 shares of Benitec Biopharma stock in a transaction dated Monday, December 29th. The stock was purchased at an average cost of $13.44 per share, with a total value of $1,040,081.28. Following the transaction, the director owned 9,700,195 shares in the company, valued at approximately $130,370,620.80. The trade was a 0.80% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders acquired 190,364 shares of company stock worth $2,442,105. 4.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG boosted its holdings in Benitec Biopharma by 458.8% in the 3rd quarter. UBS Group AG now owns 99,941 shares of the biotechnology company’s stock worth $1,402,000 after buying an additional 82,057 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Benitec Biopharma by 219.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company’s stock worth $1,286,000 after purchasing an additional 75,507 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Benitec Biopharma in the second quarter valued at about $503,000. XTX Topco Ltd purchased a new position in shares of Benitec Biopharma in the second quarter worth about $127,000. Finally, Rhumbline Advisers boosted its position in Benitec Biopharma by 11,114.0% during the second quarter. Rhumbline Advisers now owns 20,858 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 20,672 shares during the last quarter. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.